Emergent BioSolutions, Inc. (NYSE:EBS)
CAPS Rating:
A biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics. The Company operates in two business segments: biodefense and commercial.
RSS Headlines
Fool UK
Recs
Emergent BioSolutions maintains a large economic moat through it's Biothrax vaccine. Two of it's vaccines in late stage development, a typhoid vaccine candidate and a hepatitis B therapeutic vaccine candidate, uniquely positions EBS to take advantage of the expected huge growth of demand in LDC and MDC.